Paradigm Capital analyst Scott McAuley believes NervGen Pharma (NervGen Pharma Stock Quote, Chart, News TSXV:NGEN) could produce a paradigm shift in treating neurodegenerative diseases, initiating coverage on Wednesday with a “Speculative Buy” rating and target price of $5.20/share. A Vancouver-based pharmaceutical company dedicated to the treatment of nervous system damage, NervGen is in the process of […]
Raymond James analyst Rahul Sarugaser has turned his attention to Ginkgo Bioworks Holdings (Ginkgo Bioworks Stock Quote, Chart, News NYSE:DNA), initiating coverage on Wednesday with an “Outperform 2” rating and target price of $14.50/share (all figures in US dollars). Headquartered in Boston, Ginkgo Bioworks Holdings builds bespoke living cells through the use of synthetic biology, […]
Share
